The LILRB family in hematologic malignancies: prognostic associations, mechanistic considerations, and therapeutic implications
2024

The Role of LILRB Family in Blood Cancers

publication 10 minutes Evidence: moderate

Author Information

Author(s): Hodges Alan, Dubuque Rachel, Chen Shu-Hsia, Pan Ping-Ying

Primary Institution: Houston Methodist Research Institute

Hypothesis

How do LILRB proteins influence hematologic malignancies?

Conclusion

LILRB proteins are significant as diagnostic and prognostic biomarkers in blood cancers and may serve as therapeutic targets.

Supporting Evidence

  • LILRB proteins are implicated in immune evasion in cancer.
  • LILRB1 and LILRB4 are sensitive markers for acute myeloid leukemia.
  • LILRB4 expression correlates with poor outcomes in multiple myeloma.
  • LILRB proteins can influence the immune microenvironment in hematologic malignancies.

Takeaway

LILRB proteins help doctors understand and treat blood cancers better by acting as markers for diagnosis and potential treatment targets.

Methodology

This review synthesizes existing literature on LILRB proteins in hematologic malignancies.

Potential Biases

Potential bias in the interpretation of LILRB roles due to the focus on specific malignancies.

Limitations

The review primarily focuses on AML, with less data on other hematologic malignancies.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1186/s40364-024-00705-7

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication